Co-Diagnostics Inc Registered Shs CODX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CODX is a good fit for your portfolio.
News
-
Co-Diagnostics, Inc. Inaugurates New Manufacturing Facility in Utah with Ribbon Cutting Event
-
Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions
-
Co-Diagnostics, Inc. CEO Delivers Manufacturing and Commercialization Update in Conference Keynote Address
-
Co-Diagnostics, Inc. CEO to Deliver Keynote Address at MarketsandMarkets 2024 in London, England
-
Co-Diagnostics, Inc. Reports Full Year 2023 Financial Results
-
Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Influenza Multiplex PCR Test
-
Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2023 Earnings Release Date and Webcast
-
Co-Diagnostics, Inc. Shares List of Upcoming Industry Conferences and Events for February 2024
Trading Information
- Previous Close Price
- $1.14
- Day Range
- $1.09–1.19
- 52-Week Range
- $0.98–1.89
- Bid/Ask
- $1.15 / $1.27
- Market Cap
- $36.26 Mil
- Volume/Avg
- 216,760 / 60,781
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.00
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 3.76%
Company Profile
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 155
- Website
- https://www.codiagnostics.com
Valuation
|
Metric
|
CODX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.42 |
Price/Sales | 5.00 |
Price/Cash Flow | — |
Price/Earnings
CODX
Financial Strength
|
Metric
|
CODX
|
|---|---|
Quick Ratio | 10.24 |
Current Ratio | 10.81 |
Interest Coverage | — |
Quick Ratio
CODX
Profitability
|
Metric
|
CODX
|
|---|---|
Return on Assets (Normalized) | −24.87% |
Return on Equity (Normalized) | −26.94% |
Return on Invested Capital (Normalized) | −27.42% |
Return on Assets
CODX
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Brgdvsdbm | Fxbmfc | $182.7 Bil | |
SYK
| Stryker Corp | Wsnphhmw | Nzvys | $124.6 Bil | |
MDT
| Medtronic PLC | Jvxtbssq | Rxrwj | $105.2 Bil | |
BSX
| Boston Scientific Corp | Fnpgxdb | Qygqrld | $99.1 Bil | |
EW
| Edwards Lifesciences Corp | Pncccpdsd | Qvvwm | $52.0 Bil | |
DXCM
| DexCom Inc | Ngznwvzxd | Yqkbd | $51.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Bmgvzjxz | Tvs | $24.5 Bil | |
ALGN
| Align Technology Inc | Flvdbwqmz | Dwnndw | $22.7 Bil | |
PHG
| Koninklijke Philips NV ADR | Rmthhcwkg | Zfsdj | $18.3 Bil | |
PODD
| Insulet Corp | Snjcfxsy | Qghhsrf | $11.6 Bil |